Skip to main content
Contact Us
Back to Homepage
follow us on linkedin
follow us on facebook
follow us on twitter
follow us on youtube
Investors & Media
News
Events & Presentations
Financials
Quarterly Results
Annual Reports
SEC Filings
Interactive Financials
Form 8937
Stock Information
Stock Details
Analyst Coverage
Governance
Governance Documents
Committee Composition
Resources
Investor FAQs
Investor Email Alerts
ZTALMY Factsheet
Site Search
toggle main menu
News
Investors & Media
News
Events & Presentations
Financials
Quarterly Results
Annual Reports
SEC Filings
Interactive Financials
Form 8937
Stock Information
Stock Details
Analyst Coverage
Governance
Governance Documents
Committee Composition
Resources
Investor FAQs
Investor Email Alerts
ZTALMY Factsheet
Normal
Press release year list
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
12/13/2018
Marinus Pharmaceuticals Announces Pricing of Public Offering of Common Stock
12/11/2018
Marinus Pharmaceuticals Announces Public Offering of Common Stock
12/10/2018
Marinus Pharmaceuticals Announces Positive Ganaxolone Data in Women With Postpartum Depression
12/04/2018
Marinus Pharmaceuticals Phase 2 Clinical Trial Data Show Long-term Effectiveness of Ganaxolone in Reducing Seizure Frequency in CDKL5 Deficiency Disorder Patients
11/19/2018
Marinus Pharmaceuticals to Present Ganaxolone Clinical Trial Data in CDKL5 Deficiency Disorder and PCDH19-Related Epilepsy at AES
10/29/2018
Marinus Pharmaceuticals Provides Business Update and Third Quarter 2018 Financial Results
10/10/2018
Marinus Pharmaceuticals Names Dr. Rolando Gutíerrez-Esteinou as VP of Clinical Development and Pharmacovigilance
10/09/2018
Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)
10/05/2018
Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
09/25/2018
Marinus Completes Enrollment in its Magnolia Postpartum Depression Study
09/20/2018
Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
09/05/2018
Marinus Appoints Scott Braunstein, MD to its Board of Directors
08/30/2018
Marinus Pharmaceuticals to Present at the Baird Healthcare Conference
08/07/2018
Marinus Pharmaceuticals to Present at Wedbush/PacGrow Healthcare Conference
08/02/2018
Marinus Pharmaceuticals Provides Business Update and Second Quarter 2018 Financial Results
07/30/2018
Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
06/21/2018
Marinus Pharmaceuticals to Be Added to the Russell 2000 and Russell 3000 Index
06/19/2018
Marinus Pharmaceuticals Initiates Pivotal Phase 3 Trial in Children with CDKL5 Deficiency Disorder
06/15/2018
Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)
05/30/2018
Marinus Pharmaceuticals to Present at Upcoming Investor Conferences
05/14/2018
Marinus Pharmaceuticals to Present at the UBS Global Healthcare Conference
05/02/2018
Marinus Pharmaceuticals Provides Business Update and First Quarter 2018 Financial Results
04/10/2018
Ganaxolone IV Clinical Data Presented at Leading International Status Epilepticus Medical Conference
03/15/2018
Marinus Pharmaceuticals to Present at Oppenheimer Healthcare Conference
03/08/2018
Marinus Pharmaceuticals to Present at the Barclays Global Healthcare Conference
03/06/2018
Marinus Pharmaceuticals Provides Business Update and 2017 Financial Results
02/07/2018
Marinus Pharmaceuticals to Attend Upcoming Investor Conferences
02/01/2018
Marinus Appoints Michael R. Dougherty to its Board of Directors
01/23/2018
Marinus Announces Positive Preliminary Data From Children With CDKL5 Genetic Disorder